Related references
Note: Only part of the references are listed.Management of Patients with Advanced Prostate Cancer. Part I: Intermediate-/High-risk and Locally Advanced Disease, Biochemical Relapse, and Side Effects of Hormonal Treatment: Report of the Advanced Prostate Cancer Consensus Conference 2022
Silke Gillessen et al.
EUROPEAN UROLOGY (2023)
Targeting galectin-driven regulatory circuits in cancer and fibrosis
Karina V. Marino et al.
NATURE REVIEWS DRUG DISCOVERY (2023)
Investigation of the effects of isoeugenol-based phenolic compounds on migration and proliferation of HT29 colon cancer cells at cellular and molecular level
Sema Bilgin et al.
BIOORGANIC CHEMISTRY (2023)
Prostate Cancer Incidence and Mortality: Global Status and Temporal Trends in 89 Countries From 2000 to 2019
Le Wang et al.
FRONTIERS IN PUBLIC HEALTH (2022)
Best Approaches and Updates for Prostate Cancer Biochemical Recurrence
Nicholas I. Simon et al.
American Society of Clinical Oncology educational book / ASCO. American Society of Clinical Oncology. Meeting (2022)
PRESTO: A phase III, open-label study of androgen annihilation in patients (pts) with high-risk biochemically relapsed prostate cancer (AFT-19)
R. Aggarwal et al.
ANNALS OF ONCOLOGY (2022)
Modified Citrus Pectin Treatment in Non-Metastatic Biochemically Relapsed Prostate Cancer: Results of a Prospective Phase II Study
Daniel Keizman et al.
NUTRIENTS (2021)
Epidemiology and Prevention of Prostate Cancer
Giorgio Gandaglia et al.
EUROPEAN UROLOGY ONCOLOGY (2021)
Incidence and disease burden of prostate cancer from 1990 to 2017: Results from the Global Burden of Disease Study 2017
Zhen Zhai et al.
CANCER (2020)
Sweetening the hallmarks of cancer: Galectins as multifunctional mediators of tumor progression
Maria Romina Girotti et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2020)
Natural Compounds in Prostate Cancer Prevention and Treatment: Mechanisms of Action and Molecular Targets
Fabrizio Fontana et al.
CELLS (2020)
Advanced Prostate Cancer: Treatment Advances and Future Directions
Umang Swami et al.
TRENDS IN CANCER (2020)
Phytochemicals in Prostate Cancer: From Bioactive Molecules to Upcoming Therapeutic Agents
Bahare Salehi et al.
NUTRIENTS (2019)
Past, Current, and Future of Immunotherapies for Prostate Cancer
Adeline N. Boettcher et al.
FRONTIERS IN ONCOLOGY (2019)
Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review
Thomas Van den Broeck et al.
EUROPEAN UROLOGY (2019)
Summary statement on screening for prostate cancer in Europe
Eveline A. M. Heijnsdijk et al.
INTERNATIONAL JOURNAL OF CANCER (2018)
Prostate Cancer Screening
William J. Catalona
MEDICAL CLINICS OF NORTH AMERICA (2018)
Androgen Signaling in Prostate Cancer
Charles Dai et al.
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE (2017)
Galectins: emerging regulatory checkpoints linking tumor immunity and angiogenesis
Santiago P. Mendez-Huergo et al.
CURRENT OPINION IN IMMUNOLOGY (2017)
Low or No Inhibitory Potency of the Canonical Galectin Carbohydrate-binding Site by Pectins and Galactomannans
John Stegmayr et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2016)
Change in PSA velocity is a predictor of overall survival in men with biochemically-recurrent prostate cancer treated with nonhormonal agents: combined analysis of four phase-2 trials
D. L. Suzman et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2015)
EAU Guidelines on Prostate Cancer. Part II: Treatment of Advanced, Relapsing, and Castration-Resistant Prostate Cancer
Axel Heidenreich et al.
EUROPEAN UROLOGY (2014)
Resources and Biological Activities of Natural Polyphenols
An-Na Li et al.
NUTRIENTS (2014)
Management of Patients with Biochemical Recurrence After Local Therapy for Prostate Cancer
Channing J. Paller et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2013)
A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer
C. J. Paller et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2013)
Resveratrol inhibits TGF-β1-induced epithelial-to-mesenchymal transition and suppresses lung cancer invasion and metastasis
Heyong Wang et al.
TOXICOLOGY (2013)
Antiproliferative activity of peels, pulps and seeds of 61 fruits
Fang Li et al.
JOURNAL OF FUNCTIONAL FOODS (2013)
The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up
Emmanuel S. Antonarakis et al.
BJU INTERNATIONAL (2012)
Berry anthocyanidins synergistically suppress growth and invasive potential of human non-small-cell lung cancer cells
Hina Kausar et al.
CANCER LETTERS (2012)
Inhibition of Prostate Cancer Bone Metastasis by Synthetic TF Antigen Mimic/Galectin-3 Inhibitor Lactulose-L-Leucine
Olga V. Glinskii et al.
NEOPLASIA (2012)
The economic burden of prostate cancer
Claus G. Roehrborn et al.
BJU INTERNATIONAL (2011)
A Galectin-3 Ligand Corrects the Impaired Function of Human CD4 and CD8 Tumor-Infiltrating Lymphocytes and Favors Tumor Rejection in Mice
Nathalie Demotte et al.
CANCER RESEARCH (2010)
Lenalidomide in Nonmetastatic Biochemically Relapsed Prostate Cancer: Results of a Phase I/II Double-Blinded, Randomized Study
Daniel Keizman et al.
CLINICAL CANCER RESEARCH (2010)
PectaSol-C Modified Citrus Pectin Induces Apoptosis and Inhibition of Proliferation in Human and Mouse Androgen-Dependent and -Independent Prostate Cancer Cells
Jun Yan et al.
INTEGRATIVE CANCER THERAPIES (2010)
Galectins: structure, function and therapeutic potential
Ri-Yao Yang et al.
EXPERT REVIEWS IN MOLECULAR MEDICINE (2008)
Prostate specific antigen working group guidelines on prostate specific antigen doubling time
Philip M. Arlen et al.
JOURNAL OF UROLOGY (2008)
Variation in the definition of biochemical recurrence in patients treated for localized prostate cancer: The American Urological Association Prostate Guidelines for Localized Prostate Cancer update panel report and recommendations for a standard in the reporting of surgical outcomes
Michael S. Cookson et al.
JOURNAL OF UROLOGY (2007)
Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer
Nancy L. Keating et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: Recommendations of the RTOG-ASTRO Phoenix Consensus Conference
Mack Roach et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2006)
Phase II study of pomegranate juice for men with rising prostate-specific antigen following surgery or radiation for prostate cancer
Allan J. Pantuck et al.
CLINICAL CANCER RESEARCH (2006)
Predictors of prostate cancer-specific mortality after radical prostatectomy or radiation therapy
P Zhou et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy
SJ Freedland et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Marimastat in the treatment of patients with biochemically relapsed prostate cancer: A prospective randomized, double-blind, phase I/II trial
E Rosenbaum et al.
CLINICAL CANCER RESEARCH (2005)
Outcome predictors for the increasing PSA state after definitive external-beam radiotherapy for prostate cancer
MJ Zelefsky et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Surrogate end point for prostate cancer-specific mortality after radical prostatectomy or radiation therapy
AV D'Amico et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Modified citrus pectin (MCP) increases the prostate-specific antigen doubling time in men with prostate cancer: a phase II pilot study
BW Guess et al.
PROSTATE CANCER AND PROSTATIC DISEASES (2003)
Inhibition of human cancer cell growth and metastasis in nude mice by oral intake of modified citrus pectin
P Nangia-Makker et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2002)
Share Paper
